. 2014 Apr 27;14:91. doi: 10.1186/1471-2377-14-91

Table 1.

Studies included in meta-analysis

First author, year	Study type	No. of patients	Mean onabotA dose/injection	Duration of effect	Definition of duration	Country of origin
First author, year	Study type	No. of patients	Mean (±SD) units	Mean (±SD)	Definition of duration	Country of origin
Benecke 2005 [17]	Prospective, randomized, double-blind, parallel-group, noninferiority study	232	138.9 ± 46.8	94.3 ± 31.4 days	Interval between injection and first visit at which TWSTRS severity score reached 80% of baseline	Ex-US
Bihari 2005 [6]	Prospective, single-arm, crossover study	12^a	131	64.3 days	Time to reach 70% TWSTRS score	Ex-US
Brashear 2005 [3]	Retrospective	172^b	241.80-254.07	108.48 days (year 1)	Interval between treatments	US
Brashear 2000 [25]	Retrospective	60	263	15.5 ± 3.4 weeks	Interval between visits	US
Brashear 1998 [27]	Prospective, single-center study	149^c	219.8 ± 63.5	142.9 ± 85.8 days	Average time between treatments	US
Brin 2008 [29]	Prospective, open-label, multicenter study	326	187.0 ± 76.5	110.2 ± 91.8 days	Time from treatment injection to date of next injection	US/Ex-US
Brockmann 2012 [24]	Retrospective	20	175 ± 76	10.7 ± 1.9 weeks	Time between last treatment and first subjective notice of reduction of benefit from the treatment	Ex-US
Camargo 2008 [18]	Prospective, single-center study	85	151.05 ± 52.55	89.1 ± 21.8 days	Patient-reported time to return of symptoms	Ex-US
Dubinsky 1991 [28]	Prospective cohort	84	269 ± 39	107 ± 49 days	Time from initial injection until patient-reported worsening of symptoms	US
Jankovic 2003 [19]	Prospective, single-center study	119	223.9 ± 73.0	14.6 ± 5.6 weeks	Not specified	US
Jankovic 1990 [26]	Prospective cohort	205	105.4 ± 33.8	14.0 ± 6.9 weeks	Duration of peak effect	US
Maia 2010 [20]	Retrospective	67	204.79	13.01 weeks	Duration which patient had any benefit from treatment	Ex-US
Meija 2005 [21]	Retrospective	16^d	221.2 ± 129.4	15.4 ± 3.4 weeks	Not specified	US
Mohammadi 2009 [7]	Prospective cohort	44	145 ± 44	10 ± 2.4 weeks	Not specified	Ex-US
Naumann 2002 [8]	Prospective, randomized, double-blind, crossover study	59	155 ± 51	13.9 ± 2.6 weeks	Time to TWSTRS severity score ≥10 and rotational score ≥1	Ex-US
Naumann 2002 [8]	Prospective, randomized, double-blind, crossover study	68	157 ± 44	13.6 ± 2.4 weeks	Time to TWSTRS severity score ≥10 and rotational score ≥1	Ex-US
Odergren 1998 [22]	Prospective, randomized, double-blind, parallel-group study	35	152 ± 45	80.7 ± 14.4 days	Time to retreatment	Ex-US
Quagliato 2010 [30]	Prospective, randomized, double-blind study	12^e	NR	11.7 ± 3.4 weeks	Interval between day of treatment and patient-reported waning effect	Ex-US
Ranoux 2002 [23]	Prospective, randomized, double-blind, crossover study	51	104.4 ± 20.6	89.1 ± 19 days	Interval between day of treatment and patient-reported waning of effect	Ex-US

^a48 total patients; only 12 had CD. ^bCase report forms. ^c156 total patients; 149 had idiopathic CD. ^d45 total patients; 16 had CD. ^e24 total patients; 12 received onabotulinumtoxinA.

Abbreviations: NR not reported, onabotA onabotulinumtoxinA, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale.